Woolverton C J, Fotos P G, Mokas M J, Mermigas M E
J Oral Pathol. 1986 Sep;15(8):450-3. doi: 10.1111/j.1600-0714.1986.tb00656.x.
Mutagenicity of eugenol (2-methoxy-4-allylphenol) was evaluated by an in vivo eukaryotic assay in mice. A 50% lethal dose (LD50) for intraperitoneal (IP) delivery of eugenol was found to be 1109.6 mg/kg body weight (7.5% eugenol-in-saline). Oral (PO) delivery via stainless-steel, esophageal cannulation was not lethal to 14,794 mg/kg body weight (100%) eugenol. Based upon recommended procedure, 80 and 25% LD50 doses were administered IP in 250 microliter volumes. Undiluted eugenol was administered PO in 100 microliter volumes. Delivery of eugenol by both regimes to male mice induced anaphase mutations in polychromatic erythrocytes as measured by the bone marrow micronucleus test. IP delivery of both doses induced the formation of micronuclei to significant levels (P less than 0.001) compared to saline controls. PO delivery of eugenol induced a much reduced frequency of micronuclei when compared to the IP route. However, a significant increase in micronuclei was evident when this test population was compared to its control group (P less than 0.003). These results suggest that eugenol presents some mutagenic capacity in eukaryotic hosts and should be evaluated for further toxicological effects.
通过小鼠体内真核生物试验评估了丁香酚（2-甲氧基-4-烯丙基苯酚）的致突变性。发现腹腔注射丁香酚的50%致死剂量（LD50）为1109.6毫克/千克体重（7.5%丁香酚生理盐水溶液）。通过不锈钢食管插管进行口服给药，14794毫克/千克体重（100%）的丁香酚未致死。根据推荐程序，以250微升的体积腹腔注射80%和25% LD50剂量。以100微升的体积口服未稀释的丁香酚。通过这两种给药方式给雄性小鼠给药后，通过骨髓微核试验检测发现，多色红细胞中出现了后期突变。与生理盐水对照组相比，两种剂量的腹腔注射均诱导微核形成至显著水平（P<0.001）。与腹腔注射途径相比，口服丁香酚诱导的微核频率大大降低。然而，与对照组相比，该试验组的微核明显增加（P<0.003）。这些结果表明，丁香酚在真核宿主中具有一定的致突变能力，应进一步评估其毒理学效应。
